Peripheral arterial occlusive disease

Vasa - Journal of Vascular Diseases

Volumn 36, Issue 3, 2007, Pages 155-164

  Minar, Erich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antiplatelet treatment; Endovascular treatment; Peripheral arterial disease; Risk factors; Vasoactive drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NAFTIDROFURYL; PROSTAGLANDIN E1; PROSTANOID; RAMIPRIL; VASCULOTROPIN; VASOACTIVE AGENT;

ANGIOGENESIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; BYPASS SURGERY; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED CLINICAL TRIAL; EXERCISE; HUMAN; INTERMITTENT CLAUDICATION; LEG REVASCULARIZATION; LIMB ISCHEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MORTALITY; PATHOGENESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; RISK FACTOR; STENT; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

ANGIOGRAPHY, DIGITAL SUBTRACTION; ARTERIAL OCCLUSIVE DISEASES; DECISION TREES; ENDOTHELIAL CELLS; EXERCISE THERAPY; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION; VASCULAR SURGICAL PROCEDURES; VASODILATOR AGENTS;

EID: 34548204372     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.36.3.155     Document Type: Review

References (76)

1. Adam DJ, Beard JD, Cleveland T, et al. Bypass surgery versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005; 366: 1925-34.
2. Allison MA, Criqui MH, McClelland RL, et al. The Effect of Novel Cardiovascular Risk Factors on the Ethnic-Specific Odds for Peripheral Arterial Disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006; 48: 1190-7.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
4. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-8.
5. Bendermacher BL, Willigendael EM, Teijink JA, et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2006; 2: CD0052632; 31: 23-7.
6. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9.
7. Brass EP, Anthony R, Dormandy J, et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. Vasc Surg 2006; 43: 752-9.
8. Cachovan M. Could the effects of physical training be improved by means of additive pharmacotherapy? VASA 2005; 34 Suppl 68: 21-6.
9. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 1991; 83: I70-80.
10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
11. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl): 609S-626S
12. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. VASA 2004; 33: 137-44.
13. De la Haye R, Diehm C, Blume J, et al. Eine epidemiologische Untersuchung zur Einsetzbarkeit und zu den Grenzen der physikalischen Therapie/ Bewegungstherapie bei der arteriellen Verschlusskrankheit im Stadium II nach Fontaine. VASA 1992; Suppl 38: 5-40.
14. Diehm C, Kühn A, Strauss R, et al. Effects of regular training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication - a controlled study. VASA 1989; Suppl 28: 26-30.
15. Diehm C, Schuster A, Allenberg JR, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis. 2004; 172: 95-105.
16. Diehm C, Lange St, Darius H, et al. for the getABI Study Group. Association of low ankle brachial index with high mortality in primary care. Eur Heart J 2006; 27: 1743-9.
17. Diehm N, Baumgartner I, Jaff M, et al. A call for uniform reporting standards in studies assessing endovascular treatment for chronic ischaemia of lower limb arteries. Eur Heart J 2007; 28: 798-805.
18. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-months results. Circulation 2002; 106: 1505-9.
19. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005; 16: 331-8.
20. Eikelboom JW, Hirsh J, Weitz JI. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
21. Exner M, Minar E, Wagner O, Schillinger M. The role of heme oxygenase-1 promotor polymorphisms in human disease. Free Rad Biol Med 2004; 37: 1097-104.
22. Feringa HH, van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 47: 1182-7.
23. Garg PK, Tian L, Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease Circulation 2006; 114: 242-8.
24. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
25. Haynes WG, Stanford C. Periodontal disease and atherosclerosis-from dental to arterial plaque. Arterioscler Thromb Vasc Biol 2003; 23: 1309-11.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
27. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
28. Hung HC, Willet W, Merchant A, et al. Oral health and peripheral arterial disease. Circulation 2003; 107: 1152-7.
29. Izquierdo-Porrera AM, Gardner AW, Powell CC, et al. Effects of exercise rehabilitation on cardiovascular risk factors in older patients with peripheral arterial occlusive disease. J Vasc Surg 2000; 31: 670-7.
30. Klein WM, van der Graaf Y, Seegers J, et al. Dutch Iliac Stent Trial: long-term results in patients randomized for primary or selective stent placement. Radiology 2006; 238: 734-44.
31. Krankenberg H, Schlüter M, Steinkamp H, et al. Nitinol Stent implantation vs. percutaneos transluminal angioplasty in superficial femoral artery lesions up to 10 cm in lenght: the Femoral Artery Stenting Trial (FAST). Circulation 2007; 116: 285-92.
32. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
33. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins invascular disease. N Engl J Med 2006; 354: 1567-77.
34. McDermott MM, Green D, Greenland P, et al. Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index. Am J Cardiol 2003; 92: 194-9.
35. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral artery disease. Circulation 2003; 107: 757-61.
36. McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 2006; 144: 10-20.
37. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753-6.
38. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation 2000; 102: 2694-9.
39. Norgren L, Hiatt WR, Dormandy JA, et al. on behalf of the TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl 1): S1-S75.
40. Nylaende M, Abdelnoor M, Stranden E, et al. The Oslo balloon angioplasty versus conservative treatment study (OBACT) - the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2007; 33: 3-12.
41. Ohta T, Sugimoto I, Takeuchi N, et al. Indications for and limitations of exercise training in patients with intermittent claudication. VASA 2002; 31: 23-7.
42. Ouwendijk R, de Vries M, Pattynama PM, et al. Imaging peripheral arterial disease: a randomized controlled trial comparing contrast-enhanced MR angiography and multi-detector row CT angiography. Radiology 2005; 236: 1094-103.
43. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-8.
44. Perkins JM, Collin J, Creasy TS, et al. Exercise training versus angioplasty for stable claudication: long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg 1996; 11: 409-13.
45. Ponec D, Jaff MR, Swischuk J, et al. CRISP Study Investigators. The nitinol SMART stent vs. Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. J Vasc Interv Radiol 2004; 15: 911-18.
46. Radack K, Deck C. β-Adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-76.
47. Rand T, Basile A, Cejna M, et al. PTA versus carbofilmcoated stents in infrapopliteal arteries: pilot study. Cardiovasc Interv Radiol 2006; 29: 29-38.
48. Regensteiner J, Ware JJ, McCarthy W, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50: 1939-46.
49. Reiter M, Bucek RA, Stümpflen A, et al. Prostanoids in the treatment of intermittent claudication - a meta-analysis. VASA 2002; 31: 219-24.
50. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 2004; 109: 733-9.
51. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.
52. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
53. Robeer GG, Brandsma JW, van den Heuvel SP, et al. Exercise therapy for intermittent claudication: a review of the quality of randomised clinical trials and evaluation of predictive factors. Eur J Vasc Endovasc Surg 1998; 15: 36-43.
54. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26.
55. Sabeti S, Schillinger M, Amighi J, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: Propensity score-adjusted analysis. Radiology 2004; 232: 516-21.
56. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243(1): 148-57.
57. Scheffler P, de la Hamette D, Gross J, et al. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994; 90: 818-22.
58. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: 312-5.
59. Scheinert D, Biamino G, Schmidt A. Preliminary experience with DESs in tibial arteries. Endovasc Today 2006; 5: 60-2.
60. Schillinger M, Exner M, Mlekusch W, et al. Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther 2002; 9: 59-66.
61. Schillinger M, Exner M, Mlekusch W, et al. Inflammatory response to stent implantation: differences of femoral, iliac and carotid arteries. Radiology 2002; 224: 529-35.
62. Schillinger M, Exner M, Amighi J, et al. Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events in patients with advanced atherosclerosis. Circulation 2003; 108: 2323-8.
63. Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004; 25: 742-8.
64. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879-88.
65. Schlager O, Dick P, Sabeti S, et al. Stenting of the superficial femoral artery - the dark sides: restenosis, clinical deterioration and fractures. J Endovasc Ther 2005; 12: 676-84.
66. Selvin E, Erlinger TP. Prevalence of and Risk Factors for Peripheral Arterial Disease in the United States: Results From the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-43.
67. Steiner S, Niessner A, Ziegler S, et al. Endurance training increases the number of endothelial progenitor cells in patients with cardiovascular risk and coronary artery disease. Atherosclerosis 2005; 181: 305-10.
68. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427.
69. Tetteroo E, van der Graaf Y, Bosch JL, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet 1998; 351: 1153-59.
70. Tzoulaki I, Murray DG, Price JF, et al. Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am J Epidemiol 2006; 163: 334-41.
71. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007; 109: 2285-92.
72. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-7.
73. Vroegineweij D, Vos LD, Tielbeek AV, et al. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol 1997; 20: 420-5.
74. WhymanMR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomised controlled trial. J Vasc Surg 1997; 26: 551-7.
75. Yla-Herttuala S, Rissanen TT,Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49: 1015-26.
76. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.